Veracyte (VCYT) Jefferies Global Healthcare Conference 2026 summary

Business performance and financial outlook

• Achieved double-digit revenue growth for Afirma and high-20s growth for Decipher in Q1, leading to raised guidance and strong fundamentals.

• Delivered 31% EBITDA in Q1, driven by prior period collections, no result rate underspend, and profitability, with updated guidance for high to low double-digit growth.

• Decipher expected to grow over 20% in revenue, with volume outpacing revenue due to ASP headwinds.

• EBITDA margin guidance remains above 26% for the year, balancing reinvestment in new launches while maintaining a 25% long-term target.

• Strong cash position (~$440M), with disciplined M&A approach focused on strategic fit and data strategy alignment.

Product launches and innovation

• Two new growth drivers launched: one three days prior to the conference, another set for the following Monday.

• Prosigna launch supported by OPTIMA study data, expected to drive significant market impact and guideline inclusion within a year.

• TrueMRD launched with MolDX coverage, targeting recurrence monitoring in the urology channel, leveraging whole genome approach.

• Afirma continues to benefit from transcriptome advancements, with improved no result rates and cost efficiencies.

Market strategy and competitive positioning

• Prosigna aims for broad market adoption, leveraging OPTIMA data and a top-down KOL-driven approach, with an initial sales team of 10-12.

• Decipher uses a data-driven strategy to expand in high-risk and low-risk prostate cancer segments, with ongoing studies to further penetrate the market.

• Afirma gains share from competitors through academic engagement and continuous improvement, with guidance for high single to low double-digit growth.

• TrueMRD focuses on owning the tissue block and urology channel, differentiating from competitors in the med onc channel.